Hep C 101

Hepatitis C: Introduction, Clinical Manifestations, and Natural History

Real-world evaluation of eligibility for HCV therapy

In clinical practices in Italy, between January 2009 and February 2010, only 61% of patients with chronic hepatitis C were considered eligible for peginterferon/ribavirin. Reasons treatment was not indicated included patient’s age or mild disease stage. Italian Hepatologists may consider an IFN-based antiviral treatment not cost-effective in older patients with mild HCV disease. Italy has the highest prevalence rates of hepatitis C ...

Read More

HCV adapts to host immune response and DAAs

Posted on April 25, 2015

HCV is a rapidly evolving virus with a high mutation rate: adaptation to the host immune response and selection of HCV strains resistant to direct-acting antiviral therapies Hepatitis C virus (HCV) is a positive strand-enveloped ribonucleic acid (RNA) virus, and the single-stranded RNA molecule consists of a large open reading frame encoding a polyprotein precursor of approximately 3,000 residues, which is processed during and after transla...

Read More

Treatment-induced SVR is a long-term HCV cure

Posted on April 15, 2015

Study indicates that a treatment-induced SVR corresponds to a cure for Hepatitis C, and that the clinical significance of any residual trace amounts of HCV RNA seems limited A sustained viral response (SVR), defined as undetectable HCV RNA in serum 24 weeks after the end of treatment, is regarded as a cure from HCV infection. However, it has been hypothesized that residual foci of HCV infected cells with low HCV replication may still be ...

Read More

Urgent need for birth cohort hepatitis C testing

Posted on April 13, 2015

Study highlights urgent need to implement recent CDC and USPTF birth cohort Hepatitis C testing recommendations in the routine clinical environment While there have been many recent notable advances in the treatment of hepatitis C, these advances can only help those individuals who are tested and identified. Unfortunately, the proportion of unidentified anti-HCV positive persons has been estimated as ranging from 40% to 85%, and it’s ...

Read More

HCV therapy access reduces HCV-related deaths

Posted on April 12, 2015

A global reduction of HCV liver-related mortality is dependent on access to therapy Between 64 and 103 million individuals worldwide are estimated to be chronically infected with hepatitis C (HCV). Fortunately, with the advent of interferon-free therapy with SVR rates in pivotal phase 2 and 3 trials of between 92% and 100%, it’s possible to cure chronic HCV infection in more than 90% of patients with just 3 months of therapy. Unfortunately, ...

Read More

Hepatitis C: topical and comprehensive seminar

The Lancet has published a topical and comprehensive seminar on hepatitis C The March 2015 issue of the Lancet contains an authoritative seminar on hepatitis C (Webster DP, et al. Lancet. 2015;385:1124-1135). The Lancet is one of the world's leading medical journals; an independent and authoritative voice in global medicine. Dr. Daniel Webster and colleagues' comprehensive HCV seminar includes discussion on the topics of hepatitis C virology, ...

Read More

Perfectovir is a realizable goal: an HCV revolution

Posted on April 5, 2015

The development of “Perfectovir” is a realizable goal: a revolution in the treatment of Hepatitis C has begun! The key attributes of an optimal HCV treatment regimen were recently outlined by Gregory Dore and Jordan Feld in an invited review article published in the journal Clinical Infectious Diseases (Dore GJ, Feld JJ. Clin Infect Dis. 2015 Mar 11. pii: civ197. [Epub ahead of print]). These key attributes are as follows: Extremely ...

Read More

Can hepatitis C be eradicated in the US?

An important commentary by Brian Edlin and Emily Winkelstein, published in August 2014 in the journal Antiviral Research, outlined key steps that should be taken to accomplish the elimination of hepatitis C in the United States (Edlin BR, Winkelstein ER. Antiviral Res. 2014;110:79-93). This article is freely available on the online AJM Hepatitis C Resource Center (http://hepcresource.amjmed.com). Accomplishing the goal of eradicating hepatitis C ...

Read More

HCV RNA Testing in HCV Seropositive Patients

Posted on April 1, 2015

Only 48% of HCV Seropositive Patients Undergo HCV RNA Testing and Only 5% Initiate Therapy The Centers for Disease Control and Prevention recommends one-time hepatitis C virus (HCV) testing of individuals born between 1945 and 1965, with follow-up RNA testing for those with reactive serology. A study published last year in the journal Open Forum Infectious Diseases put perspective on the clinical practice challenges being faced in light of ...

Read More

Addressing the Global Hepatitis C Crisis

Posted on February 19, 2015
Hepatitis C Virus

The number of individuals suffering from the devastating consequences of chronic Hepatitis C (HCV) infection is increasing worldwide. HCV infection is typically asymptomatic for decades but up to 80% of people infected with HCV will develop chronic disease. Progressive liver fibrosis is an important consequence of chronic HCV infection, with resultant cirrhosis that may lead to liver failure (decompensation) and hepatocellular carcinoma (HCC). ...

Read More